Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Valsartan (Primary)
- Indications Cardiomyopathies
- Focus Therapeutic Use
- Acronyms VANISH
- 01 Feb 2018 Planned End Date changed from 1 Nov 2018 to 1 Jul 2019.
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 01 May 2017 Trial Design published in the American Heart Journal.